Could gamithromycin be a viable treatment for rabbit pasteurellosis? This study explores the pharmacokinetic (PK) and pharmacodynamic (PD) properties of gamithromycin in rabbits, evaluating its potential as a treatment for *Pasteurella multocida*, a common cause of respiratory disease. While effective in treating respiratory diseases in cattle and swine, gamithromycin has not been utilized in rabbits, making this research novel and significant. The PK analysis revealed favorable properties, including high bioavailability and low plasma protein binding. The study determined plasma AUC/MIC ratios associated with bacteriostatic, bactericidal, and bacterial eradication effects. Subcutaneous administration of gamithromycin reached therapeutic concentrations in rabbit plasma, suggesting its potential for treating rabbit pasteurellosis. These findings offer valuable insights for veterinary medicine, potentially expanding treatment options for this prevalent and troublesome infection in rabbits.
As a publication in BMC Veterinary Research, this study directly aligns with the journal's focus on advancements in veterinary medicine. By investigating a novel application of gamithromycin in rabbits, the research contributes to the journal's mission of disseminating high-quality research relevant to animal health and disease management.